Clinical Trial Update: Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase IB/II study evaluating ribociclib in combination with trastuzumab and letrozole in postmenopausal HR+, HER2-positive advanced breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Letrozole (letrozole)
• Ribociclib (ribociclib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Yonsei University | Conditions: HER2-positive Breast Cancer, Postmenopausal | Phase 1, Phase 2 | Status: UNKNOWN